[Double-blind study on the anti-convulsive effect of phenobarbital and valproate in the Lennox syndrome].
In a double-blind crossover trial valproate was compared with phenobarbital with regard to anticonvulsive activity and tolerance in 17 epileptic children (mean age 55 +/- 26 months) with Lennox syndrome. Valproate in association with a phenobarbital dose reduced by about 40% proved to be to a statistically significant degree more active against epileptic seizures than phenobarbital alone. No difference in the effect on the EEG tracings was observed. Valproate appeared to be somewhat more active than phenobarbital with regard to behaviour, but the difference was not significant. Tolerance to both products was equally good.
D001569:Benzodiazepines / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D010634:Phenobarbital / Q000627:therapeutic use*; D014631:Valerates / Q000627:therapeutic use*; D014635:Valproic Acid / Q000627:therapeutic use*
D014631:Valerates; D001569:Benzodiazepines; D014635:Valproic Acid; D010634:Phenobarbital
Doppeltblind-Untersuchung über die antikonvulsive Wirkung von Phenobarbital und Valproat beim Lennox-Syndrom.